CBAY - CymaBay: Live And Die By The FDA
There is no guarantee that the FDA will lift the clinical hold on the development of Seladelpar. - CymaBay May 11, 2020 - 10-Q
Introduction
CymaBay Therapeutics (CBAY) is a clinical-stage biopharmaceutical company with a 3-product pipeline specializing primarily in the development of therapeutics for underserved or unmet liver conditions. They recently pivoted into therapeutics targeting diabetes with two candidates in early-stage development. In late 2019, phase 2b clinical trial results of their flagship therapeutic Seladelpar showed some indication of potential liver damage in trial participants. These findings resulted in a significant negative